Chimeric antigen receptor T cell（CAR-T）therapy has achieved remarkable successes in treating refractory leukemia and other hematologic malignancies in the past ten years. At present，the FDA has approved six CAR-T cell products for hematologic malignancies including leukemia，lymphoma，etc.，highlighting the arrival of the era of immunotherapy and cell therapy for cancer. A large number of studies have indicated the potential of CAR-T cells in solid tumors. However，data from clinical trials was far from satisfactory yet. Obstacles interfering with the therapeutic effects of CAR-T cell therapy in solid tumors have been identified，including lack of reliable tumor-associated antigens，physical barriers within tumors，metabolic stress，immunosuppressive tumor environments， etc. Efforts should be made to further investigate the underlying mechanisms，and gene engineering technologies holds great potential for generation of more effective CAR-T strategies. This review aimed to provide a landscape view of recent progress for CAR-T cell therapy in solid tumors and discussed the challenges and future directions of CAR-T cell therapy.